VERACYTE, INC. (VCYT): what the price assumes

In the published model solve dated 2026-Q2, anchored at $46.09, VERACYTE, INC. (VCYT) is priced for today's economics sustained for ~17.5 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/VCYT

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 6: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 14.3% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.8 years.

Reconcile: at the x-ray's 9.3% required return this reads ~6.7 years; the models below use their own rates.

How unusual the bet is: elevated

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=18)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Among the diagnostics companies it is measured against, this is the only one earning an operating profit, at 8.4% of revenue on a trailing basis, while NTRA runs at minus 13.0% and GH at minus 41.4%.
• The business is not the problem; the price is. It stands at roughly 99 times what the company earned in operating profit last year, a level no standard valuation approach comes close to reaching.
• Second-quarter results are due July 30, 2026, the next check on whether Decipher Prostate and Afirma volumes keep outrunning the cost of delivering them.

Bull Case

One number separates this company from the field it gets compared with, and it is not a growth rate. It is the operating margin, which ran at 8.4% over the trailing year. Set that against the closest comparables and the contrast is not subtle: NTRA converts minus 13.0% of $2.501 billion of revenue into operating profit while growing 36.6%, and GH runs at minus 41.4% on $1.080 billion while growing 39.6%. Growth in molecular diagnostics is abundant. Profit is scarce. If that 8.4% ever returns to zero, everything below stops mattering, which is precisely why it is the figure to watch.

The reason it exists comes down to what gets sold and to whom. Testing revenue comes from Decipher Prostate and Afirma, delivered to physicians in the United States, with third-party payers invoiced on delivery of the patient report. These are established tests running through an existing laboratory, not screening assays waiting on a first coverage decision, and volume in both was strong enough in the March 2026 quarter to push the cost of testing revenue up 18% as staffing and infrastructure were added behind them. Growth that arrives through a lab already built is a different economic event from growth that requires building one.

The funding history is unusual for this industry, and the company states it without embellishment: "Beginning in 2023, our operations have been financed primarily by cash flows generated by our revenue." The business produced roughly 155.3 million dollars of free cash flow over the trailing year. There are no meaningful funded borrowings, and the liquid holdings are the dull sort, including treasury bills of 100.9 million dollars and certificates of deposit of 75.0 million dollars at March 31, 2026. A diagnostics company that does not have to visit the capital markets gets to plan on a different timescale from one that does.

Management has also shown a willingness to stop doing things, which in this sector is rarer than starting them. The biopharmaceutical services and contract manufacturing operations previously run in France were discontinued following restructuring proceedings affecting the French subsidiary in August 2025. That shrank a revenue line on purpose. A services business removed rather than subsidised leaves the laboratory carrying the fixed costs on its own, which is where the margin comes from.

The concession is straightforward. This company is not growing anywhere near the pace of the cohort; its historical rate runs closer to 17% against roughly 40% for the two nearest names. The bull case does not pretend otherwise. It argues that growth paid for out of the company's own profit compounds for the people who already own the shares, while growth paid for by issuing new ones compounds for somebody else.

Bear Case

For a business that generates its own cash, the share count is heading the wrong way. It has risen about 3.4% a year over the four years to March 2026. Stock-based compensation ran near 50 million dollars against free cash flow of about 155.3 million over the trailing year, so close to a third of what the operation produces is routed to employees in equity before an outside shareholder sees any of it. Nothing is being repurchased to offset it. The money accumulates in treasury bills while ownership of it quietly thins, and the arithmetic of that trade only works if the equity being handed out is buying growth worth more than the dilution costs.

Profitability here is recent, and the company itself declines to treat it as settled. Operating profit for the trailing year came to about $43.2 million against a five-year average of roughly $10 million, which is a polite way of saying four of those five years contributed almost nothing. The accumulated deficit stood at $348.9 million as of March 31, 2026. Having reported net income of $28.7 million for the March quarter, the filing goes straight on to say "we may not sustain profitability in the future." Boilerplate in form, accurate in substance.

The revenue depends on decisions taken by other people, and the filings are candid about it. The 10-K states outright that "We depend on a few payers for a significant portion of our revenue". The commercial model delivers first and argues about payment afterwards: the company takes "the assignment of benefits and the risk of cash collection from the third-party payer". And payment, once received, is not necessarily final, because "Payers may attempt to recoup prior payments after review, sometimes after significant time has passed, which would impact future revenue." Revenue that an insurer can reach back and reclaim years later is a weaker asset than the income statement makes it look.

Which brings the discussion to the price. It stands at roughly 99 times last year's operating profit, and no family of valuation method reaches it. The price sits about 484% above the asset-based approaches, roughly 191% above the earnings-power approaches and about 112% above the peer-multiple approaches. Even the growth-based approaches, which credit the historical growth rate in full, land beneath it. Unanimity among methods that usually argue with each other is information in itself.

Read literally, the multiple asks for growth held at the fastest rate the business can fund out of its own profit for a period measured in decades. That literal reading deserves salt: an arithmetic stretched that far is really a signal that the price has left the range these tools describe usefully, not a forecast of anything. The direction of the signal is not ambiguous, though. Only about 14% of comparable fast growers sustained their pace even ten years, and the calculation is violently sensitive to interest rates: a single point on the cost of capital swings the answer by several years. A profitable, self-funding diagnostics company is a good thing to own. The entire argument is about what it should cost.

Valuation

The methods are unanimous here, which is rare enough to lead with: not one family reaches today's price. It sits about 484% above the asset-based approaches, roughly 191% above the earnings-power approaches and about 112% above the peer-multiple approaches. Even the growth-based approaches, which project the recent revenue trajectory forward in full, land underneath it.

The earnings-power reading makes sense as soon as the history is visible. That approach capitalises an average of the last five years of operating profit and assumes no growth at all, and the average in question is only about $10 million, against roughly $43.2 million in the trailing year. Four of those five years contributed close to nothing. So the method is not saying the business is worth little. It is saying the profit stream is about a year old, and a single year of evidence capitalised into perpetuity is a thin foundation.

Set against operating profit, the price works out at roughly 99 times it. Inverting that into a required growth path produces a horizon measured in decades, which is less a projection than a statement that the price has moved past what this arithmetic can usefully describe. Take it as a direction and not a number. The direction is that today's price needs the profit that showed up last year to keep compounding at a self-funded maximum for a very long time, and among comparable fast growers only about 14% managed even a decade of that.

The cohort makes the case for the premium and the case against it in the same breath. This is the only profitable company among its closest comparables, with NTRA at a minus 13.0% operating margin on $2.501 billion of revenue and GH at minus 41.4% on $1.080 billion, while RDNT, a much larger imaging business, converts 2.9% on $2.144 billion. Scarcity of profit inside a growing category is a genuine reason to pay a premium. What it does not settle is the size of one.

Solvency is not a live question. The company carries no meaningful funded borrowings, its liquid holdings include treasury bills of 100.9 million dollars and certificates of deposit of 75.0 million dollars as of March 31, 2026, and operations have financed the business since 2023. The pressure sits on the other side of the ledger. The share count has risen about 3.4% a year over four years, so the per-share arithmetic works slightly against the holder even as the aggregate improves.

Catalysts

The next print is imminent. The company said on July 9, 2026 that second-quarter results would be released on July 30, 2026. Two lines are worth reading together when it lands: testing revenue from Decipher Prostate and Afirma, and the cost of delivering it, which rose 18% in the March 2026 quarter on higher volume, higher staffing and infrastructure built for expected future growth. Volume outrunning cost is the whole operating thesis; cost outrunning volume is the whole risk.

A structural change is still working through the comparisons. Biopharmaceutical and other revenue fell because the biopharmaceutical services, contract manufacturing and contract development work previously conducted in France was discontinued following restructuring proceedings affecting the French subsidiary as of August 2025. Product revenue, largely international sales of the Prosigna breast cancer kit, was flat over the same comparison. Year-on-year growth figures through the middle of 2026 therefore carry a deliberately shrinking line inside them, and the underlying testing business is growing faster than the headline suggests.

The sell side has rarely been this split on one company. Guggenheim raised its target to $65 from $45 with a Buy rating on June 26, 2026. Canaccord raised its own to $60 from $42 while keeping a Hold on July 13. Piper Sandler initiated at Overweight on July 14, describing the company as a rare cash-generative diagnostics laboratory. Morgan Stanley raised its number to $47 from $37 and kept an Underweight rating on July 9. Every one of those numbers moved higher and the recommendations still point in opposite directions, which is the same disagreement described above showing up somewhere else: nobody argues about whether the company makes money, and everybody argues about the multiple.

Peer Cohorts (Per Segment, With Filing Citations)

Diagnostic tests & biopharmaceutical services (reported)

• NTRA (NATERA, INC.)
• FY2025 10-K: …for other NIPTs. As a result, if our tests do not perform as expected or favorably in comparison to competitive tests, our operating results, reputation, and business will suffer. We may also become subject to legal claims arising from such limitations, errors, or inaccuracies. ​ 37 Table of Contents Our tests use a…
• FY2025 10-K: …primarily face competition from various companies that develop and commercialize molecular diagnostic tests in women's health, oncology, and organ transplant rejection. Our competitors in the NIPT space include BGI; BillionToOne Inc.; Fulgent Genetics; Illumina, through its subsidiary Verinata; Laboratory Corporation…
• GH (GUARDANT HEALTH, INC.)
• FY2025 10-K: …and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue, subject to assessment of the risk of cumulative future revenue reversal. Biopharma and data Biopharma and data revenue includes amounts derived from the delivery of the…
• FY2025 10-K: …utility and health economics from use of our tests to patients, physicians and payers; and ▪ pursuing FDA and other regulatory approval internationally of our tests to facilitate reimbursement and global market access. • Strengthen our relationships with customers by: ▪ demonstrating the utility of our products in…
• RDNT (RadNet, Inc.)
• FY2025 10-K: …Service. Our operations comprise two segments for financial reporting purposes for this reporting period, Imaging Centers and Digital Health. For further financial information about these segments, see Note 5, Segment Reporting, in the notes accompanying our consolidated financial statements included in this report.…
• FY2025 10-K: …our commercial Digital Health business, building on a global customer base of more than 2,000 organizations. Our strategy is to expand adoption of our comprehensive portfolio across Enterprise Operations, Enterprise Imaging, and Clinical AI/Population Health. We plan to grow commercial revenue by: 6 • Increasing…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.